MA29244B1 - Compositions permettant d'immuniser contre une mycobacterie - Google Patents

Compositions permettant d'immuniser contre une mycobacterie

Info

Publication number
MA29244B1
MA29244B1 MA30124A MA30124A MA29244B1 MA 29244 B1 MA29244 B1 MA 29244B1 MA 30124 A MA30124 A MA 30124A MA 30124 A MA30124 A MA 30124A MA 29244 B1 MA29244 B1 MA 29244B1
Authority
MA
Morocco
Prior art keywords
antigen
compositions
immunizing against
vector expressing
against mycobacteria
Prior art date
Application number
MA30124A
Other languages
English (en)
Inventor
Helen Mcshane
Ansar A Pathan
Adrian Hill
Sarah C Gilbert
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0500102.9A external-priority patent/GB0500102D0/en
Application filed by Isis Innovation filed Critical Isis Innovation
Publication of MA29244B1 publication Critical patent/MA29244B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

L'INVENTION CONCERNE UNE MÉTHODE PERMETTANT DE GÉNÉRER UNE RÉPONSE IMMUNITAIRE DES LYMPHOCYTES T CHEZ UN HÔTE. CETTE MÉTHODE CONSISTE À ADMINISTRER UN VACCIN VECTORISÉ QUI COMPREND UN VECTEUR VIRAL NON RÉPLIQUANT OU À RÉPLICATION ALTÉRÉE EXPRIMANT LE PRODUIT DE TRADUCTION D'UN GÈNE 85A DE L'ANTIGÈNE MYCOBACTÉRIEN. L'INVENTION CONCERNE ÉGALEMENT DES VACCINS VECTORISÉS ET LEURS UTILISATIONS. L'INVENTION CONCERNE ENFIN UNE MÉTHODE PERMETTANT D'INDUIRE UNE RÉPONSE DES LYMPHOCYTES T MÉMOIRE CD8 ET CD4 CONTRE UN ANTIGÈNE AU MOYEN D'UN VECTEUR EXPRIMANT UN ANTIGÈNE OU UN FRAGMENT IMMUNOGÈNE DE CE DERNIER.
MA30124A 2005-01-05 2007-08-03 Compositions permettant d'immuniser contre une mycobacterie MA29244B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500102.9A GB0500102D0 (en) 2005-01-05 2005-01-05 Method for generating a memory t cell response
US64980405P 2005-02-03 2005-02-03

Publications (1)

Publication Number Publication Date
MA29244B1 true MA29244B1 (fr) 2008-02-01

Family

ID=36062509

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30124A MA29244B1 (fr) 2005-01-05 2007-08-03 Compositions permettant d'immuniser contre une mycobacterie

Country Status (16)

Country Link
EP (1) EP1833507B1 (fr)
JP (2) JP2008526823A (fr)
KR (1) KR20070108518A (fr)
AP (1) AP2007004059A0 (fr)
AU (1) AU2006204382B2 (fr)
BR (1) BRPI0606165A2 (fr)
CA (1) CA2592756A1 (fr)
CY (1) CY1111549T1 (fr)
EA (1) EA012436B1 (fr)
HR (1) HRP20110402T1 (fr)
IL (2) IL184414A (fr)
MA (1) MA29244B1 (fr)
MX (1) MX2007008182A (fr)
NZ (1) NZ560468A (fr)
PL (1) PL1833507T3 (fr)
WO (1) WO2006072787A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1817061B1 (fr) * 2004-12-01 2011-07-27 Aeras Global Tuberculosis Vaccine Foundation Electroporation of mycobacterium et surexpression d'antigenes dans des mycobacteries
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
DK2421557T3 (en) 2009-04-24 2019-03-25 Statens Seruminstitut TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION
WO2011113953A1 (fr) * 2010-03-19 2011-09-22 Red Flag Diagnostics Gmbh Procédé in vitro pour la détermination rapide de l'état d'un patient lié à l'infection par mycobacterium tuberculosis
US10357555B2 (en) 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
SG11201605595YA (en) * 2014-01-09 2016-08-30 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
RU2665817C1 (ru) * 2017-10-25 2018-09-04 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Вакцина рекомбинантная противотуберкулезная и адъювант для нее
EP3937967A4 (fr) * 2019-03-14 2022-12-14 Sanford Burnham Prebys Medical Discovery Institute Peptides nanomolaires et dérivés pour moduler de manière différentielle les récepteurs de l'éphrine

Also Published As

Publication number Publication date
IL217235A0 (en) 2012-01-31
EP1833507B1 (fr) 2011-03-16
EA012436B1 (ru) 2009-10-30
PL1833507T3 (pl) 2011-08-31
EA200701440A1 (ru) 2008-02-28
WO2006072787A8 (fr) 2006-09-14
JP2013010775A (ja) 2013-01-17
KR20070108518A (ko) 2007-11-12
CA2592756A1 (fr) 2006-07-13
IL184414A (en) 2012-01-31
WO2006072787A1 (fr) 2006-07-13
BRPI0606165A2 (pt) 2009-06-02
AU2006204382A1 (en) 2006-07-13
EP1833507A1 (fr) 2007-09-19
MX2007008182A (es) 2008-02-19
IL184414A0 (en) 2007-10-31
AP2007004059A0 (en) 2007-08-31
AU2006204382B2 (en) 2011-05-12
JP2008526823A (ja) 2008-07-24
HRP20110402T1 (hr) 2011-07-31
NZ560468A (en) 2010-05-28
CY1111549T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
MA29244B1 (fr) Compositions permettant d'immuniser contre une mycobacterie
Cunningham et al. Vaccine development: From concept to early clinical testing
Wu et al. Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice
Wakim et al. Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection
Selvapandiyan et al. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis
Kallen et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive® vaccines
Stevenson et al. DNA vaccines against cancer come of age
Araújo et al. CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2
WO1999042564A3 (fr) Presentation des antigenes aux lymphocytes t au moyen de cellules d'apoptose
WO2002061113A3 (fr) Vaccin moleculaire superieur a base d'arn autoreplicatif, d'adn suicide ou de vecteur d'adn nu, qui lie un antigene a un polypeptide qui favorise la presentation de l'antigene
Bivona et al. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine
Rice et al. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines
Thompson et al. Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants
SG162818A1 (en) Multivalent entrain-and-amplify immunotherapeutics for carcinoma
Soundarya et al. Current trends in tuberculosis vaccine
Roggendorf et al. The woodchuck: a model for therapeutic vaccination against hepadnaviral infection
Steffensen et al. Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses
WO2006113622A3 (fr) Vaccination directe de la moelle osseuse
Weinberger et al. The influence of antigen targeting to sub-cellular compartments on the anti-allergic potential of a DNA vaccine
Motozono et al. The SARS-CoV-2 Omicron BA. 1 spike G446S mutation potentiates antiviral T-cell recognition
Mazumder et al. PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2
Kurstak Modern vaccinology
Uddbäck et al. PB1 as a potential target for increasing the breadth of T-cell mediated immunity to Influenza A
ZA200706389B (en) Compositions for immunizing against mycobacterium
Stifter et al. A tumor-specific neoepitope expressed in homologous/self or heterologous/viral antigens induced comparable effector CD8+ T-cell responses by DNA vaccination